Polycystic kidney disease interventions: Difference between revisions

	Polycystic kidney disease Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Polycystic kidney disease from other Diseases
Epidemiology and Demographics
Risk Factor
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Future or Investigational Therapies
Case Studies
Case #1
Polycystic kidney disease interventions On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Polycystic kidney disease interventions All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Polycystic kidney disease interventions
CDC on Polycystic kidney disease interventions
Polycystic kidney disease interventions in the news
Blogs on Polycystic kidney disease interventions
Directions to Hospitals Treating Polycystic kidney disease
Risk calculators and risk factors for Polycystic kidney disease interventions

VisualWikitext

Revision as of 18:52, 7 June 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]

Overview

There are no recommended therapeutic interventions for the management of [disease name].

OR

[Name of intervention] is not the first-line treatment option for patients with [disease name]. [Name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and [indication 3]

OR

The mainstay of treatment for [disease name] is medical therapy/surgery. [Name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].

OR

The feasibility of [name of intervention] depends on the stage of [disease or malignancy] at the time of diagnosis.

OR

[Name of intervention] is the mainstay of treatment for [disease or malignancy].

Indications

[Name of intervention] is not the first-line treatment option for patients with [disease name]. [Name of intervention] is usually reserved for patients with either:

[Indication 1]
[Indication 2]
[Indication 3]

OR

The mainstay of treatment for [disease name] is medical therapy/surgery. [Name of intervention] is usually reserved for patients with either:

[Indication 1]
[Indication 2]
[Indication 3]

[Name of Intervention]

The feasibility of [name of intervention] depends on the stage of [disease or malignancy] at the time of diagnosis.

OR

[Name of intervention] is the mainstay of treatment for [disease or malignancy].

OR

The mechanism of [name of intervention] is as follows:

Contraindications

References

Template:WH Template:WS

@@ Line 1: / Line 1: @@
+__NOTOC__
 {{Polycystic kidney disease}}
-{{CMG}}; {{AE}}
+{{CMG}}; {{AE}} {{MKA}}
 ==Overview==
-Definitive diagnosis using genetic testing is only possible in around half of the patients with a clinical diagnosis of ADPKD. Given the cost and low sensitivity, genetic testing is reserved for specific cases and is not a preferred method of diagnosis.
+There are no recommended therapeutic interventions for the management of [disease name].
-==Genetic Testing==
+OR
-Although both causative gene loci for ADPKD have been defined, genetic diagnosis is not the preferred modality due to its elevated cost and low sensitivity. Despite being feasible, the various type of mutations including frame insertions/deletions, non-canonical splice site alterations, or combined missense changes often make the identification of pathogenic mutations very complex. Futhermore, definitive disease-causing mutations are usually detected in only 41 to 63% of cases approximately. <ref name="pmid17574468">{{cite journal| author=Garcia-Gonzalez MA, Jones JG, Allen SK, Palatucci CM, Batish SD, Seltzer WK et al.| title=Evaluating the clinical utility of a molecular genetic test for polycystic kidney disease. | journal=Mol Genet Metab | year= 2007 | volume= 92 | issue= 1-2 | pages= 160-7 | pmid=17574468 | doi=10.1016/j.ymgme.2007.05.004 | pmc=PMC2085355 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17574468  }} </ref><ref name="pmid17582161">{{cite journal| author=Rossetti S, Consugar MB, Chapman AB, Torres VE, Guay-Woodford LM, Grantham JJ et al.| title=Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. | journal=J Am Soc Nephrol | year= 2007 | volume= 18 | issue= 7 | pages= 2143-60 | pmid=17582161 | doi=10.1681/ASN.2006121387 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17582161  }} </ref>
+[Name of intervention] is not the first-line treatment option for patients with [disease name]. [Name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and [indication 3]
+OR
+The mainstay of treatment for [disease name] is medical therapy/surgery. [Name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].
+OR
+The feasibility of [name of intervention] depends on the stage of [disease or malignancy] at the time of diagnosis.
+OR
+[Name of intervention] is the mainstay of treatment for [disease or malignancy].
+==Indications==
+[Name of intervention]  is not the first-line treatment option for patients with [disease name]. [Name of intervention] is usually reserved for patients with either:
+*[Indication 1]
+*[Indication 2]
+*[Indication 3]
+OR
+The mainstay of treatment for [disease name] is medical therapy/surgery. [Name of intervention] is usually reserved for patients with either:
+*[Indication 1]
+*[Indication 2]
+*[Indication 3]
+==[Name of Intervention] ==
+The feasibility of [name of intervention] depends on the stage of [disease or malignancy] at the time of diagnosis.
+OR
+[Name of intervention] is the mainstay of treatment for [disease or malignancy].
+OR
+The mechanism of [name of intervention] is as follows:
+==Contraindications==
 ==References==
-{{reflist|2}}
+{{Reflist|2}}
 {{WH}}
 {{WS}}
+[[Category: (name of the system)]]